argenx SE
NASDAQ:ARGX
argenx SE
NASDAQ:ARGX
Price:
384.465 USD
-3.6%
Updated:
May 8, 2024
Section:
Relative Value
The Relative Value of one
ARGX
stock under the Base Case scenario is
856.129
USD.
Compared to the current market price of 384.465 USD,
argenx SE
is
Undervalued by 55%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ARGX
Relative Value
Base Case
856.129
USD
Undervaluation 55%
Valuation Multiples
Multiples Across Competitors
ARGX Competitors Multiples
argenx SE Competitors
argenx SE Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NL |
|
argenx SE
NASDAQ:ARGX
|
21.8B USD | 19.1 | -79.3 | -66.2 | -48.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
282.8B USD | 5.2 | 58.7 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
163.1B USD | 5.5 | 43.4 | 18.4 | 30.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.8B USD | 11 | 30 | 24.2 | 25.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.5B USD | 8.1 | 27.3 | 22.1 | 24.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36 | 21.8 | 27 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81B USD | 3 | 167.4 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.5B USD | 9 | -7.8 | -8.5 | -7.5 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.1B USD | 3.3 | 27.5 | 14.1 | 17.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.3 | 46 | 63.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
